Alzamend Neuro, Inc.

Alzamend Neuro, Inc. (ALZN) priced its initial public offering on Jun 15, 2021 at $5.00 per share, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $424.6M. Spartan Capital was lead-left underwriter. Olshan Frome Wolosky advised the company and Haynes and Boone advised the underwriters.

Alzamend Neuro, Inc. is a preclinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases and psychiatric disorders. It has two current product candidates, and its primary target is Alzheimer's disease.

Status

IPO

Ticker

ALZN

Exchange

Nasdaq Capital Market

Priced

Jun 15, 2021

IPO price

$5.00

Market cap at IPO price

$424.6M

First filed

May 10, 2021

Underwriters

Spartan Capital

Company counsel

Olshan Frome Wolosky

Underwriters' counsel

Haynes and Boone

Sector

Biotech & pharma

Country / state

GA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.